Rising Serum CA-125 Levels Within the Normal Range is Strongly Associated Recurrence Risk and Survival of Ovarian Cancer

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2020 Sep 4

PMID 32878632

Citations 18

Authors

Szymon Piatek

Grzegorz Panek

Zbigniew Lewandowski

Mariusz Bidzinski

Dominika Piatek

Przemyslaw Kosinski

Miroslaw Wielgos

Affiliations

Soon will be listed here.

Abstract

Background: In clinical practice alterations in CA-125 concentration within normal range in patients with ovarian cancer after first-line treatment are common. Even minor increase in CA-125 concentration is associated with patients' anxiety and difficult interpretation and counselling for clinicians. The aim of this study was to evaluate the significance of CA-125 fluctuations within reference level in patients who suffered from ovarian cancer with complete response after first-line treatment.

Results: 168 patients with epithelial ovarian cancer, who achieved complete remission after first line treatment were enrolled in the study. CA-125 concentration assessment was carried out during follow up visits. The recurrence of the disease was diagnosed on the first appearance of symptoms: clinical, radiological or histopathological/cytological. PFS and 5-year survival rate was calculated with Kaplan-Meier plots. Statistical analysis was performed with SAS / STAT® 9.4 / 14.4, SAS Institute Inc., Cary, NC, USA, 2017. Median concentration of CA-125 after first-line therapy was 10 U/ml. Increasing CA-125 concentration by > 5 U/ml, 3 and 6 months after the treatment was associated with higher risk of relapse (HR = 7.6, p < 0.0001 and HR = 5.29, p < 0.0001 respectively). 5-year survival rate was significantly lower in patients with increased CA-125 by 5 U/ml, 3 and 6 months after therapy (56.79% vs 0 and 50.62% vs 15.55%).

Conclusions: Increased concentration of CA-125 by > 5 U/ml within normal range, 3 and 6 months after treatment was unfavorable prognostic factor in ovarian cancer patients with complete response to primary therapy.

Citing Articles

The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.

Momenimovahed Z, Mazidimoradi A, Allahqoli L, Salehiniya H Cancer Rep (Hoboken). 2025; 8(3):e70142.

PMID: 40067023 PMC: 11894717. DOI: 10.1002/cnr2.70142.

Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging in Magnetic Resonance in the Assessment of Peritoneal Recurrence of Ovarian Cancer in Patients with or Without BRCA Mutation.

Jankowska-Lombarska M, Grabowska-Derlatka L, Kraj L, Derlatka P Cancers (Basel). 2024; 16(22).

PMID: 39594694 PMC: 11591656. DOI: 10.3390/cancers16223738.

rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering.

Krishnan S, Sharma D, Nazeer Y, Bose M, Rajkumar T, Jayaraman G Antib Ther. 2024; 7(3):256-265.

PMID: 39262441 PMC: 11384895. DOI: 10.1093/abt/tbae018.

An increase of serum CA-125 to two times of nadir level strongly predicts the image-identified relapse of serous ovarian cancer.

Du K, Li Q, Huang J, Chan D, Li J, Chang X Sci Rep. 2024; 14(1):14986.

PMID: 38951620 PMC: 11217381. DOI: 10.1038/s41598-024-65760-4.

MUC16: clinical targets with great potential.

Zhang X, Hong L, Ling Z Clin Exp Med. 2024; 24(1):101.

PMID: 38758220 PMC: 11101557. DOI: 10.1007/s10238-024-01365-5.

References

Makar A, Kristensen G, Kaern J, Bormer O, Abeler V, Trope C . Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992; 79(6):1002-10. View

Davidson N, Khanna S, Kirwan P, Bircumshaw D . Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol). 1991; 3(1):32-6. DOI: 10.1016/s0936-6555(05)81038-6. View

Santillan A, Garg R, Zahurak M, Gardner G, Giuntoli 2nd R, Armstrong D . Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005; 23(36):9338-43. DOI: 10.1200/JCO.2005.02.2582. View

Badulescu F, Badulescu A, Schenker M, Popescu C, Stoica Z . The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Rom J Morphol Embryol. 2006; 46(4):329-34. View

Rustin G, Nelstrop A, McClean P, Brady M, McGuire W, Hoskins W . Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996; 14(5):1545-51. DOI: 10.1200/JCO.1996.14.5.1545. View

Levy T, Weiser R, Boaz M, Ben Shem E, Golan A, Menczer J . Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response. Int J Gynecol Cancer. 2012; 22(8):1344-8. DOI: 10.1097/IGC.0b013e3182691254. View

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

Liu P, Alberts D, Monk B, Brady M, Moon J, Markman M . An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25(24):3615-20. DOI: 10.1200/JCO.2006.09.4540. View

Wang F, Ye Y, Xu X, Zhou X, Wang J, Chen X . CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013; 6(1):14. PMC: 3576242. DOI: 10.1186/1757-2215-6-14. View

10.

Wilder J, Pavlik E, Straughn J, Kirby T, Higgins R, DePriest P . Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol. 2003; 89(2):233-5. DOI: 10.1016/s0090-8258(03)00051-9. View

11.

Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J . Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers. 2000; 15(2):147-52. DOI: 10.1177/172460080001500204. View

12.

Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P . The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. Eur J Cancer. 2015; 51(15):2104-2119. DOI: 10.1016/j.ejca.2015.08.001. View

13.

Gronlund B, DEHN H, Hogdall C, Engelholm S, Jorgensen M, Norgaard-Pedersen B . Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer. 2005; 15(5):836-43. DOI: 10.1111/j.1525-1438.2005.00145.x. View

14.

Petri A, Hogdall E, Christensen I, Kjaer S, Blaakaer J, Hogdall C . Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS. 2006; 114(5):359-63. DOI: 10.1111/j.1600-0463.2006.apm_397.x. View

15.

Horowitz N, Miller A, Rungruang B, Richard S, Rodriguez N, Bookman M . Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015; 33(8):937-43. PMC: 4348639. DOI: 10.1200/JCO.2014.56.3106. View

16.

Azad N, Annunziata C, Steinberg S, Minasian L, Premkumar A, Chow C . Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 2008; 112(8):1726-32. DOI: 10.1002/cncr.23374. View

17.

Kim H, Park N, Chung H, Kim J, Song Y, Kang S . Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie. 2008; 31(6):315-20. DOI: 10.1159/000131270. View